|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:affects
|
bacterial RNA synthesis
|
|
gptkbp:affiliatedWith
|
gptkb:rifamycin_antibiotics
|
|
gptkbp:alsoKnownAs
|
gptkb:rifampin
|
|
gptkbp:approvedBy
|
gptkb:FDA
1971
|
|
gptkbp:ATCCode
|
gptkb:J04AB02
|
|
gptkbp:CASNumber
|
gptkb:13292-46-1
|
|
gptkbp:chemicalFormula
|
C43H58N4O12
|
|
gptkbp:combines
|
gptkb:isoniazid
gptkb:ethambutol
gptkb:pyrazinamide
|
|
gptkbp:contraindication
|
gptkb:liver_disease
|
|
gptkbp:discoveredBy
|
gptkb:Piero_Sensi
gptkb:Maria_Teresa_Timbal
|
|
gptkbp:discoveredIn
|
gptkb:Lepetit_Pharmaceuticals
1965
|
|
gptkbp:drugInteraction
|
gptkb:warfarin
protease inhibitors
oral contraceptives
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:firstMarketedBy
|
gptkb:Ciba-Geigy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rifampicin
|
|
gptkbp:inducesEnzyme
|
gptkb:CYP2C9
gptkb:CYP2C19
gptkb:CYP3A4
|
|
gptkbp:KEGGID
|
D00410
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial DNA-dependent RNA polymerase
|
|
gptkbp:meltingPoint
|
183–188 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
822.94 g/mol
|
|
gptkbp:origin
|
gptkb:Streptomyces_mediterranei
|
|
gptkbp:pregnancyCategory
|
C (US)
B2 (Australia)
|
|
gptkbp:PubChem_CID
|
5381226
CHEMBL1368
DB01045
|
|
gptkbp:resistantTo
|
mutation in rpoB gene
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
rash
hepatotoxicity
gastrointestinal upset
flu-like syndrome
orange discoloration of body fluids
|
|
gptkbp:UNII
|
V6J7C52204
|
|
gptkbp:usedFor
|
tuberculosis
brucellosis
leprosy
Legionnaires' disease
meningococcal prophylaxis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:protein
|
|
gptkbp:bfsLayer
|
4
|